CADL catalyst calendar

Candel Therapeutics, Inc.

Upcoming catalysts
3
Cash runway
33.5 months
Cash & investments
$202M
Phase 3 programs
2

Candel Therapeutics, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Biological Products, (No Diagnostic Substances).

The next scheduled catalyst is Next quarterly earnings (projected) on October 15, 2026, a projected date rather than a confirmed one. There are 3 upcoming events on record.

Cash runway is approximately 33.5 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.

Across 7 concluded trials, 100% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
October 15, 2026 est. Next quarterly earnings (projected) Earnings —
February 15, 2027 A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec Trial Milestone Phase 2
October 22, 2031 Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA) Trial Milestone Phase 3

Track CADL alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open CADL in the tracker

Recent history

DateEventTypePhase
September 10, 2026 8-K filed: Leadership change, Reg FD disclosure Corporate —
September 9, 2026 8-K filed: Reg FD disclosure Filing —
August 13, 2026 Quarterly results filed (8-K) Earnings —
June 16, 2026 8-K filed: Leadership change Corporate —
May 15, 2026 8-K filed: Reg FD disclosure Filing —
May 14, 2026 Quarterly results filed (8-K) Earnings —
March 12, 2026 Quarterly results filed (8-K) Earnings —
February 23, 2026 8-K filed: Material agreement, Other event Corporate —
February 19, 2026 Quarterly results filed (8-K) Earnings —
December 5, 2025 8-K filed: Reg FD disclosure Filing —
November 13, 2025 Quarterly results filed (8-K) Earnings —
October 14, 2025 Quarterly results filed (8-K) Earnings —
August 21, 2025 8-K filed: Material agreement Corporate —
August 14, 2025 Quarterly results filed (8-K) Earnings —
June 24, 2025 8-K filed: Material agreement, Reg FD disclosure Corporate —
June 23, 2025 8-K filed: Leadership change, Reg FD disclosure Corporate —
June 6, 2025 8-K filed: Leadership change, Reg FD disclosure Corporate —
May 28, 2025 8-K filed: Reg FD disclosure, Other event Filing —
May 22, 2025 8-K filed: Reg FD disclosure Filing —
May 13, 2025 Quarterly results filed (8-K) Earnings —
April 23, 2025 8-K filed: Reg FD disclosure Filing —
December 31, 2024 CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC Trial Milestone Phase 2
November 15, 2024 Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES) Trial Milestone Phase 2
August 15, 2024 Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer Trial Milestone Phase 3
June 30, 2023 GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade Gliomas Trial Milestone Phase 1
December 1, 2021 Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung Cancer Trial Milestone Phase 1

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.